| TA160 |
Osteoporosis - primary prevention (TA160) |
|
-
-
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Whether or not a postmenopausal woman with osteoporosis is offered one of these drugs to prevent bone fractures will depend on her age, her bone density and how many risk factors for fracture and indicators of fragile bones she has.
In principle, alendronate is recommended as a possible treatment for preventing bone fractures in postmenopausal women who have had osteoporosis diagnosed but have not had a fracture.
If a woman can't take alendronate, risedronate and etidronate are recommended under certain circumstances as possible alternative treatments to prevent fractures.
If a woman can't take alendronate or either risedronate or etidronate, then strontium ranelate is recommended under certain circumstances as a possible alternative treatment to prevent fractures.
Raloxifene is not recommended as a treatment for preventing fractures in postmenopausal women with osteoporosis who have not had a fracture.
The guidance says that women who are 75 or over may not need a bone scan to diagnose their osteoporosis.
Update 26 January 2011
NICE has published updated final guidance on preventing osteoporotic fractures following a reconsideration of the use of strontium ranelate for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women.
In accordance with the Court of Appeal’s ruling on the technology appraisals of drugs for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women, NICE asked the manufacturer of strontium ranelate to submit additional evidence. After having examined this additional evidence on strontium ranelate and an independent expert review of the evidence very carefully, the new independent Appraisal Committee reached the same conclusions as the original Appraisal Committee, and so the recommendations on strontium ranelate remain unchanged from those published originally. Consultees then had a chance to appeal against this decision but no appeals were received.
NICE guidance on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the prevention and treatment of osteoporotic fragility fractures in postmenopausal women therefore remains unchanged.
-
Other information
How this guidance was produced
Background information
This page was last updated: 26 January 2011
-
Guidance formats
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- Patient version (MS Word)
- TA160 Alendronad, etidronad, risedronated, strontiwm ranelad a ralocsiffen ar gyfer atal torri esgyrn mewn merched ar ôl diwedd y mislif sydd ag osteoporosis nad ydynt wedi cael toriad: deall canllawiau NICE (fformat MS Word)
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
